Condition
Immune Effector Cell Associated Neurotoxicity Syndrome clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Immune Effector Cell Associated Neurotoxicity Syndrome clinical trials that are recruiting, at sites in 3 countries (most in United States (2), France (1), China (1)). By phase: Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Immune Effector Cell Associated Neurotoxicity Syndrome clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients | — | Boston, Massachusetts | Recruiting | Feb 11, 2026 |
| Remote rehabilitation for people receiving CAR-T cell therapy | — | Salt Lake City, Utah | Recruiting | Feb 5, 2026 |
| Characterizing extracellular vesicles and blood–brain barrier changes during CAR‑T therapy to understand ICANS | Phase 4 | Saint-Etienne | Recruiting | Nov 26, 2024 |
| Understanding brain changes in patients with neurotoxicity from CAR T-cell therapy | — | Shijiazhuang, Hebei | Recruiting | Dec 8, 2022 |
All recruiting trials (4)
-
Seeing if DCog Short on an iPad can spot neurotoxicity in CAR-T patients
This study tests whether a self-report iPad tool called DCog Short can help identify neurotoxicity in people receiving CAR-T cell therapy.
-
Remote rehabilitation for people receiving CAR-T cell therapy
This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.
-
Characterizing extracellular vesicles and blood–brain barrier changes during CAR‑T therapy to understand ICANS
This research will try to see if tracking extracellular vesicles in blood and MRI markers of blood–brain barrier change can help detect or explain ICANS in adults receiving CAR‑T cell therapy.
-
Understanding brain changes in patients with neurotoxicity from CAR T-cell therapy
This study is trying to understand how CAR T-cell therapy affects the brain in patients who develop neurotoxicity, by looking at brain scans and certain chemicals in their spinal fluid.
Related topics
Quick answers
How many Immune Effector Cell Associated Neurotoxicity Syndrome clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (2 trials), France (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.